Please check your internet connection and try again.
# Tamsulosin (Urimax)
## Overview
Tamsulosin is a selective alpha-1 adrenergic receptor antagonist that preferentially blocks alpha-1A receptors in the prostate and bladder neck, causing smooth muscle relaxation and improved urinary flow.
## Primary Indications
* Signs and symptoms of Benign Prostatic Hyperplasia (BPH).
* Off-label: Medical Expulsive Therapy (MET) for distal ureteral calculi.
## Adult Dosing
* **BPH:** 0.4 mg orally once daily, taken 30 minutes after the same meal each day. If no response after 2–4 weeks, dose may be increased to 0.8 mg once daily.
* **MET (Ureteral Stones):** 0.4 mg orally once daily (duration typically 2–4 weeks).
## Pediatric Dosing
* Not indicated for pediatric use. Safety and efficacy in children have not been established.
## Dose Adjustments
* **Renal Impairment:** No dosage adjustment indicated for mild to moderate impairment. Use caution in severe renal impairment (CrCl < 10 mL/min); data are limited.
* **Hepatic Impairment:** No dosage adjustment indicated for mild to moderate hepatic impairment. Use with caution in severe hepatic impairment (not formally studied).
## Contraindications
* Known hypersensitivity to tamsulosin or any component of the formulation.
## Adverse Effects
* **Common:** Dizziness, headache, abnormal ejaculation (retrograde ejaculation), rhinitis, orthostatic hypotension.
* **Serious:** Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery, syncope, priapism, severe hypotension/angina.
## Key Drug Interactions
* **Strong CYP3A4/2D6 Inhibitors (e.g., ketoconazole, clarithromycin, paroxetine):** May significantly increase tamsulosin exposure. Use with caution or avoid.
* **PDE-5 Inhibitors (e.g., sildenafil, tadalafil):** Concurrent use may lead to additive hypotensive effects; initiate only if stable on alpha-blocker therapy.
* **Antihypertensives:** Increased risk of orthostatic hypotension.
## Monitoring
* Baseline and periodic blood pressure (especially upon initiation or dose titration).
* Assessment of urinary symptoms (e.g., AUA Symptom Score).
* Monitor for signs of cardiovascular adverse events (dizziness, fainting).
## Clinical Pearls
* **Administration:** Must be taken 30 minutes after the same meal daily to ensure consistent absorption. Do *not* crush, chew, or open capsules.
* **Surgical Precaution:** Inform ophthalmologists of current or recent tamsulosin use before cataract or glaucoma surgery, as the medication is associated with Intraoperative Floppy Iris Syndrome (IFIS).
* **Orthostasis:** Advise patients to rise slowly from a sitting or lying position, especially during the first few days of therapy or after a dose increase.
* **Efficacy:** Unlike 5-alpha-reductase inhibitors (e.g., finasteride), tamsulosin does not reduce prostate size and does not affect PSA levels.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical protocols and local prescribing guidelines may vary. Always verify current prescribing information, contraindications, and drug interactions against institutional formularies or official drug labels (e.g., FDA-approved package inserts) before prescribing or administering medication.
